Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865237 | 0.90 | LMNA (0.65) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL8409695 | 0.85 | CYP3A4 (0.53) | LMNACASP6ALDH1A1TSHRMAPK1 | |
| SCHEMBL452336 | 0.84 | ALDH1A1 (0.58) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL4634186 | 0.84 | LMNA (0.62) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL3392676 | 0.83 | LMNA (0.87) | LMNACASP6ALDH1A1TSHRHCAR3 | |
| SCHEMBL2902973 | 0.82 | LMNA (0.60) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL3708951 | 0.82 | LMNA (0.56) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL1759017 | 0.82 | LMNA (0.56) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL1509549 | 0.82 | TSHR (0.60) | LMNACASP6ALDH1A1TSHRTPMT | |
| SCHEMBL8841185 | 0.80 | CASP6 (0.62) | LMNACASP6ALDH1A1TSHRTPMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926714-A1 | ISOTOPICALLY SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | Nycomed GmbH (DE) | 2008-06-04 | — | — | EP | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| WO-2007023135-A1 | ISOTOPICALLY SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NYCOMED GMBH (DE) | 2007-03-01 | — | — | WO | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| EP-0583324-B1 | HAIR-DYEING AGENT | HENKEL KGAA (DE) | 1994-12-21 | — | — | EP | disclosed |
| EP-0583324-A1 | HAIR-DYEING AGENT. | HENKEL KGAA (DE) | 1994-02-23 | — | — | EP | disclosed |
| WO-1992020320-A1 | HAIR-DYEING AGENT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | LMNA 1062/4885CASP6 2125/4885ALDH1A1 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.